Active, not recruitingPHASE2, PHASE3NCT03570931

A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Studying Infantile neuroaxonal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biojiva LLC
Principal Investigator
Peter Milner, MD
Chief Medical Officer
Intervention
RT001(drug)
Enrollment
19 enrolled
Eligibility
10 years · All sexes
Timeline
20182022

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03570931 on ClinicalTrials.gov

Other trials for Infantile neuroaxonal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Infantile neuroaxonal dystrophy

← Back to all trials